1. Home
  2. IMMP

IMMP

Immutep Limited

Logo Immutep Limited

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 2:32pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Founded: N/A Country:
Australia
Australia
Employees: N/A City: N/A
Market Cap: 296.0M IPO Year: N/A
Target Price: $8.50 AVG Volume (30 days): 138.3K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.25 EPS Growth: N/A
52 Week Low/High: $1.50 - $3.90 Next Earning Date: 04-30-2024
Revenue: $4,576,733 Revenue Growth: 47.55%
Revenue Growth (this year): 62.78% Revenue Growth (next year): 316.81%

Share on Social Networks: